ABL Diagnostics expands into viral safety with TEXCELL assets

ABL Diagnostics said it has taken over TEXCELL’s activities and assets, adding viral safety, virology and bacteriology capabilities to its molecular diagnostics business. The move broadens the French company’s reach into biologics, biopharma and sample security as demand rises for infectious risk testing and characterization.

Why it matters: - ABL Diagnostics is moving beyond molecular diagnostics into viral safety, a field tied to vaccines, biologics, cell and gene therapies, and other regulated life sciences products. - The expanded portfolio could give the company a broader role in both detecting pathogens and helping secure biological samples and products. - The company now has a wider technology base to sell to laboratories, biotechs and pharmaceutical manufacturers.

What happened: - ABL Diagnostics said on Sept. 10, 2026, that it had strengthened its technology and intellectual property portfolio after taking over TEXCELL’s activities and assets. - The company is based in Woippy, France, and is listed on Euronext Paris under the ticker ABLD. - The acquisition adds expertise in viral safety alongside ABL Diagnostics’ existing molecular diagnostics business. - The combined portfolio now includes new products, technologies and services in virology and bacteriology.

The details: - The acquired assets include a patented technology tied to EP 10306347.5 for quantifying infectious virus from reference infectious standards. - That technology measures viral infectivity through the response of host cells. - The platform has potential for automation and high-throughput processing. - ABL Diagnostics said the addition complements its capabilities in detecting, identifying and characterizing infectious agents at the molecular level. - The company now covers work that ranges from sample and biologic-product security to pathogen detection and molecular characterization. - The company cited growing demand for characterization, quantification, elimination and inactivation solutions as biopharma and biotech markets expand. - ABL Diagnostics’ existing products include UltraGene PCR detection and DeepChek DNA sequencing genotyping. - The company also markets syndromic real-time PCR tests and Nadis®, a patient medical record system used in more than 200 hospitals in France for HIV and hepatitis care. - ABL Diagnostics said it commercializes its products worldwide through its own sales team and exclusive distributors across all continents. - The company said its business now extends into virology, biosafety testing and biopharmaceutical development through TEXCELL. - ABL Diagnostics also sells products and services from CDL Pharma under an intra-group strategic agreement in place since the second half of 2025. - The company says its molecular biology products generate recurring revenue and span one of the largest microbiology application portfolios.

Between the lines: - The TEXCELL deal looks designed to move ABL Diagnostics further up the value chain, from identifying infectious agents to helping assess and control their risk. - That broader platform could make the company more relevant to drug developers and manufacturers that need both testing and safety support. - Mohammed Errafyqy, TEXCELL’s commercial lead, said the combination opens a wider value chain from securing samples and biologics to detecting and characterizing pathogens. - Dr. Chalom Sayada, ABL Diagnostics’ chief executive, said the acquisition significantly expands the company’s technology scope and adds a strong viral safety capability.

What's next: - ABL Diagnostics is likely to market the combined offering to labs, biotechs and pharmaceutical companies seeking viral safety, characterization and infectious disease testing services. - The company also appears positioned to develop new products and technologies from the TEXCELL assets as demand for biosafety and biologics testing grows. - The next test will be whether the broader portfolio translates into new commercial traction beyond ABL Diagnostics’ core molecular diagnostics business.

The bottom line: - ABL Diagnostics is using TEXCELL to become a broader infectious-risk and biosafety platform, not just a diagnostics company. - More information